GSK's Exdensur Approved in China for Severe Asthma, First Ultra-Long-Acting Biologic

summarizeSummary

GSK announced that China's NMPA has approved Exdensur (depemokimab) for severe asthma, marking it as the first and only ultra-long-acting biologic for the condition in the country.

check_boxKey Events

• China NMPA Approval

  China's National Medical Products Administration (NMPA) approved Exdensur (depemokimab) for severe asthma with an eosinophilic phenotype in patients aged 12 and older.

• First Ultra-Long-Acting Biologic

  Exdensur is the first and only ultra-long-acting biologic for severe asthma in China, offering a significant treatment option for over 2 million affected individuals.

• Strong Clinical Efficacy

  The approval is supported by SWIFT-1 and SWIFT-2 Phase III trials, which showed a significant reduction in asthma exacerbations and hospitalizations.

• Global Market Expansion

  This approval follows previous market authorizations for Exdensur in the US, Japan, EU, and UK, further expanding its global presence.

auto_awesomeAnalysis

This approval expands GSK's market reach for Exdensur into China, a significant market with over 2 million severe asthma patients. The drug's 'first and only' ultra-long-acting biologic status in China provides a competitive advantage, building on its prior approvals in the US, EU, UK, and Japan. This development strengthens GSK's respiratory portfolio and is expected to contribute positively to future revenue streams by addressing a substantial unmet medical need.